BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Conclusion: Targeting BRAF alterations represents a promising new therapeutic approach for a restricted subset of oncogene-addicted NSCLC. Prospect ive trials refining this strategy are ongoing. A next step will probably aim at combining BRAF inhibitors and immunotherapy or alternatively improve a multilevel mitogen-activated protein kinase (MAPK) pathway blockade by combining with ERK inhibitors.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: State of the Art: Concise Review Source Type: research